Agilent Technologies to acquire CDMO Biovectra for $925M

Katherine Lewin

News Reporter

Agilent Technologies plans to buy Canadian CDMO Biovectra in a $925 million deal, which Agilent says will deepen its focus on oligonucleotides and CRISPR. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Agilent Technologies to acquire CDMO Biovectra for $925M

Katherine Lewin

News Reporter

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

Exclusive: Influential Democrat will oppose Biosecure Act ahead of House vote

Astellas CEO talks future beyond Xtandi as Japanese drugmaker puts roots in Boston

BridgeBio sticks to script for ATTR-CM as Alnylam cleans up ‘typo’ snafu

Roche's Spark loses CEO to RNA upstart; Ex-Elevation Oncology chief takes over at Affimed

Lilly inks obesity deal with seed-stage RNA startup as its genetic medicines effort enters the spotlight

How to secure full enrollment and a 30x ROI: A conversation with the CEO of the boutique enrollment agency doing just ...

Ag­i­lent Tech­nolo­gies to ac­quire CD­MO Biovec­tra for $925M

News Reporter

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Agilent Technologies to acquire CDMO Biovectra for $925M